Discrimination of tropical forest types, dominant species, and mapping of functional guilds by hyperspectral and simulated multispectral Sentinel-2 data

To answer new scientific and ecological questions and monitor multiple forest changes, a fine scale characterization of these ecosystems is needed, and could imply the mapping of specific species, of detailed forest types, and of functional composition. This characterization can be now provided by the novel Earth Observation tools. This study aims to contribute to understanding the innovation in forest and ecological research that can be brought in by advanced remote sensing instruments, and proposes the guild mapping approach as a tool to efficiently monitor the varied tropical forest resources. We evaluated, in tropical Ghanaian forests, the ability of airborne hyperspectral and simulated multispectral Sentinel-2 data, and derived vegetation indices and textures, to: distinguish between two different forest types; to discriminate among selected dominant species; and to separate trees species grouped according to their functional guilds: Pioneer, Non Pioneer Light Demanding, and Shade Bearer. We then produced guild classification maps for each area using hyperspectral data. Our results showed that with both hyperspectral and simulated Sentinel-2 data these discrimination tasks can be successfully accomplished. Results also stressed the importance of texture features, especially if using the lower spectral and spatial Sentinel-2 resolution data, and highlighted the important role of the new Sentinel-2 data for ecological monitoring. Classification results showed a statistically significant improvement in overall accuracy using Support Vector Machine, over Maximum Likelihood approach. We proposed the functional guilds mapping as an innovative approach to: (i) monitor compositional changes, especially with respect to the effects of global climate change on forests, and particularly in the tropical biome where the occurrence of hundreds of species prevents mapping activities at species level; (ii) support large-scale forest inventories. The imminent Sentinel-2 data could serve to open the road for the development of new concepts and methods in forestry and ecological research

The fitness for the Ageing Brain Study II (FABS II): protocol for a randomized controlled clinical trial evaluating the effect of physical activity on cognitive function in patients with Alzheimer's disease

Background: Observational studies have documented a potential protective effect of physical exercise in older adults who are at risk for developing Alzheimer's disease. The Fitness for the Ageing Brain II (FABS II) study is a multicentre randomized controlled clinical trial (RCT) aiming to determine whether physical activity reduces the rate of cognitive decline among individuals with Alzheimer's disease. This paper describes the background, objectives of the study, and an overview of the protocol including design, organization and data collection methods

The global pharmacy workforce: a systematic review of the literature

The importance of health workforce provision has gained significance and is now considered one of the most pressing issues worldwide, across all health professions. Against this background, the objectives of the work presented here were to systematically explore and identify contemporary issues surrounding expansion of the global pharmacy workforce in order to assist the International Pharmaceutical Federation working group on the workforce

Effectiveness of balance training exercise in people with mild to moderate severity Alzheimer's disease: protocol for a randomised trial

BACKGROUND: Balance dysfunction and falls are common problems in later stages of dementia. Exercise is a well-established intervention to reduce falls in cognitively intact older people, although there is limited randomised trial evidence of outcomes in people with dementia. The primary objective of this study is to evaluate whether a home-based balance exercise programme improves balance performance in people with mild to moderate severity Alzheimer's disease. METHODS/DESIGN: Two hundred and fourteen community dwelling participants with mild to moderate severity Alzheimer's disease will be recruited for the randomised controlled trial. A series of laboratory and clinical measures will be used to evaluate balance and mobility performance at baseline. Participants will then be randomized to receive either a balance training home exercise programme (intervention group) from a physiotherapist, or an education, information and support programme from an occupational therapist (control group). Both groups will have six home visits in the six months following baseline assessment, as well as phone support. All participants will be re-assessed at the completion of the programme (after six months), and again in a further six months to evaluate sustainability of outcomes. The primary outcome measures will be the Limits of Stability (a force platform measure of balance) and the Step Test (a clinical measure of balance). Secondary outcomes include other balance and mobility measures, number of falls and falls risk measures, cognitive and behavioural measures, and carer burden and quality of life measures. Assessors will be blind to group allocation. Longitudinal change in balance performance will be evaluated in a sub-study, in which the first 64 participants of the control group with mild to moderate severity Alzheimer's disease, and 64 age and gender matched healthy participants will be re-assessed on all measures at initial assessment, and then at 6, 12, 18 and 24 months. DISCUSSION: By introducing a balance programme at an early stage of the dementia pathway, when participants are more likely capable of safe and active participation in balance training, there is potential that balance performance will be improved as dementia progresses, which may reduce the high falls risk at this later stage. If successful, this approach has the potential for widespread application through community based services for people with mild to moderate severity Alzheimer's disease. TRIAL REGISTRATION: The protocol for this study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12608000040369)